Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 18.09 |
Low | 18.09 |
Bid | -- |
Offer | -- |
Previous close | 18.94 |
Average volume | 599.00 |
---|---|
Shares outstanding | 124.32m |
Free float | 118.76m |
P/E (TTM) | -- |
Market cap | 2.34bn USD |
EPS (TTM) | -4.65 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 18:51 BST.
More ▼
Press releases
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
- Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
- Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
- Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
- Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
More ▼